Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM9NYHT)

Drug Name
LY2787106 Drug Info
Indication
Disease Entry ICD 11 Status REF
Anemia 3A00-3A9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM9NYHT

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepcidin (HAMP) TTPCG5T HEPC_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Hepcidin (HAMP) DTT HAMP 10.14 3.018 4.372 4.315
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Anemia
ICD Disease Classification 3A00-3A9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Hepcidin (HAMP) DTT HAMP 5.37E-01 0.18 0.47
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01340976) A Phase 1 Study of LY2787106 in Cancer and Anemia. U.S. National Institutes of Health.
2 A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017 Mar 21;10(1):73.